chr7:140419127:> Detail (hg19) (BRAF)

Information

Genome

Assembly Position
hg19 chr7:140,419,127-140,624,729
hg38 chr7:140,719,327-140,924,929 

HGVS

Type Transcript Protein
Summary

MGeND

Clinical significance
Variant entry
GWAS entry
Disease area statistics Show details

Frequency

[No Data.]

Prediction

[No Data.]

ClinVar

Clinical Significance
Review star [No Data.]
Show details
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
Disease Drug EL ET ED CS VO TR Pubmed Links
colorectal cancer B Prognostic Supports Better Outcome Somatic 5 28486044 Detail
gastrointestinal stromal tumor Regorafenib C Predictive Does Not Support Sensitivity/Response Somatic 2 27371698 Detail
gastrointestinal stromal tumor Regorafenib C Predictive Supports Resistance Somatic 1 22614970 Detail
Solid Tumor Trametinib B Predictive Does Not Support Sensitivity/Response Somatic 4 31924734 Detail
DisGeNET
Score Disease name Description Source Pubmed Links
0.012 squamous cell carcinoma NA BeFree,GAD,LHGDN Detail
0.002 Carcinoma, Transitional Cell NA GAD Detail
0.002 Neoplastic Cell Transformation NA GAD Detail
<0.001 cerebellar ataxia NA BeFree Detail
<0.001 Cerebellar Neoplasms NA BeFree Detail
<0.001 Malignant tumor of cervix NA BeFree Detail
<0.001 chordoma NA BeFree Detail
0.002 Chromosome Aberrations NA GAD Detail
<0.001 Congenital chromosomal disease NA BeFree Detail
<0.001 ulcerative colitis NA BeFree Detail
0.036 Colonic Neoplasms NA BeFree,GAD,LHGDN Detail
0.007 Colonic Polyps NA BeFree,GAD Detail
0.216 Colorectal Neoplasms TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphory... BeFree,CTD_human,GAD,LHGDN 25239454 Detail
0.007 Hereditary nonpolyposis colorectal neoplasms NA GAD,LHGDN Detail
0.002 Common Bile Duct Neoplasms NA GAD Detail
0.003 Conjunctival Neoplasms NA LHGDN Detail
0.240 craniopharyngioma NA BeFree,CTD_human,ORPHANET Detail
<0.001 cystadenoma NA BeFree Detail
<0.001 Cystadenoma, Mucinous NA BeFree Detail
<0.001 dermoid cyst The molecular profile of the adenocarcinoma showed a mutation in KRAS and wild-t... BeFree 25039399 Detail
<0.001 diarrhea NA BeFree Detail
<0.001 DiGeorge syndrome NA BeFree Detail
0.002 Pathological Dilatation NA GAD Detail
0.002 Dyslexia, Acquired NA GAD Detail
0.002 ectodermal dysplasia NA GAD Detail
0.005 Endometrial Neoplasms NA GAD,LHGDN Detail
<0.001 endometriosis NA BeFree Detail
0.002 Eosinophilia NA GAD Detail
<0.001 epilepsy Further analyses will be required in order to better understand the meaning of B... BeFree 25937573 Detail
<0.001 Epilepsies, Partial The aim of this study was to verify the presence of BRAF mutations in a series o... BeFree 25937573 Detail
0.002 Esophageal Neoplasms NA GAD Detail
<0.001 Exanthema We report a patient with BRAF mutant metastatic melanoma treated with the BRAFi/... BeFree 24922191 Detail
<0.001 Exanthema Combining a BRAF inhibitor with a MEK inhibitor, which may block paradoxical MAP... BeFree 25014231 Detail
<0.001 fibrosarcoma NA BeFree Detail
<0.001 Flatulence NA BeFree Detail
0.002 Gingival Neoplasms NA GAD Detail
0.001 goiter NA BeFree Detail
0.003 nodular goiter NA BeFree,GAD Detail
0.002 congenital heart defects NA GAD Detail
<0.001 Hepatolenticular Degeneration NA BeFree Detail
<0.001 HIV Infections NA BeFree Detail
0.002 Hyperplasia NA GAD Detail
<0.001 hypothyroidism NA BeFree Detail
0.002 Immunologic Deficiency Syndromes NA GAD Detail
0.001 influenza None of the 198 thyroid nodules were positive for K-RAS 61, N-RAS 12/13, or H-RA... BeFree 26166089 Detail
<0.001 Infratentorial Neoplasms NA BeFree Detail
0.001 keratoacanthoma However vemurafenib, a type I mutant BRAF V600 inhibitor, induces an array of pr... BeFree 25185693 Detail
<0.001 keratosis NA BeFree Detail
<0.001 actinic keratosis NA BeFree Detail
0.002 Language Disorders NA GAD Detail
0.001 chronic lymphocytic leukemia BRAF inhibitor-associated ERK activation drives development of chronic lymphocyt... BeFree 25329694 Detail
<0.001 Leukemia, Myelocytic, Acute NA BeFree Detail
<0.001 Myeloid Leukemia, Chronic NA BeFree Detail
<0.001 Leukemia, Myelomonocytic, Chronic NA BeFree Detail
<0.001 Leukemia, Plasma Cell NA BeFree Detail
<0.001 prolymphocytic leukemia NA BeFree Detail
0.127 Lung Neoplasms NA CTD_human,GAD,LHGDN Detail
0.012 Lymphatic Metastasis NA GAD Detail
<0.001 Lymphoma, Follicular NA BeFree Detail
<0.001 Lymphoproliferative Disorders NA BeFree Detail
0.005 Malignant neoplasm of stomach The results demonstrated that EGFR phosphorylation was markedly inhibited in gas... BeFree,GAD 25625229 Detail
0.005 Malignant neoplasm of stomach Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastri... BeFree,GAD 25815786 Detail
0.005 Malignant neoplasm of stomach BRAF activated non-coding RNA (BANCR) promoting gastric cancer cells proliferati... BeFree,GAD 26248136 Detail
0.122 Mandibular Neoplasms NA CTD_human,GAD Detail
0.002 Maxillary Neoplasms NA GAD Detail
<0.001 medulloblastoma NA BeFree Detail
<0.001 meningioma NA BeFree Detail
0.003 Mesothelioma NA LHGDN Detail
<0.001 Microphthalmos NA BeFree Detail
0.002 Mouth Neoplasms NA GAD Detail
0.003 Nasal Polyps NA BeFree,LHGDN Detail
0.002 Nasopharyngeal Neoplasms NA GAD Detail
<0.001 Neck Neoplasms NA BeFree Detail
0.017 Neoplasm Invasiveness NA GAD Detail
0.007 Neoplasm Recurrence, Local NA GAD Detail
0.002 Neoplasms, Germ Cell and Embryonal NA GAD Detail
0.005 Neoplasms, Multiple Primary NA GAD Detail
0.003 Neoplasms, Radiation-Induced NA BeFree,GAD Detail
<0.001 Neoplastic Syndromes, Hereditary NA BeFree Detail
0.003 nephrotic syndrome NA LHGDN Detail
<0.001 Nervous System Neoplasms NA BeFree Detail
<0.001 neurilemmoma NA BeFree Detail
0.002 neuroblastoma Using the Snapshot assay, mutation statuses were detected for EGFR, Kirsten rate... BeFree 24823994 Detail
0.004 neurofibromatosis 1 The molecular biology of these GIST, originally defined as KIT/PDGFRA wild-type ... BeFree,GAD 25239601 Detail
0.004 neurofibromatosis 1 Moving beyond BRAFV600 targeting, a number of other molecular subsets--such as m... BeFree,GAD 25993155 Detail
<0.001 Nodule The medical records of the 137 patients with >5 mm FVPTCs and known BRAF mutatio... BeFree 24548081 Detail
0.248 Noonan syndrome NA BeFree,CTD_human,GAD,ORPHANET Detail
<0.001 oligodendroglioma NA BeFree Detail
0.004 ovarian carcinoma NA BeFree Detail
<0.001 Pain NA BeFree Detail
0.007 Pancreatic Neoplasm NA GAD,LHGDN Detail
0.003 pancreatitis NA LHGDN Detail
<0.001 panniculitis NA BeFree Detail
<0.001 pituitary adenoma NA BeFree Detail
<0.001 Pituitary Diseases NA BeFree Detail
0.003 Pituitary Neoplasms NA LHGDN Detail
0.002 Adenomatous Polyposis Coli NA BeFree Detail
0.019 polyps BRAF and KRAS mutant traditional serrated adenomas are morphologically related b... BeFree,LHGDN 25216220 Detail
0.019 polyps These polyps contain BRAF mutations and are prone to epigenetic methylation that... BeFree,LHGDN 25602793 Detail
0.019 polyps Cancer (214 BRAF mutant, 122 BRAF wild type) and polyp (59 serrated polyps, 40 c... BeFree,LHGDN 25613750 Detail
0.005 Precancerous Conditions NA BeFree,GAD Detail
0.003 Prostatic Neoplasms NA BeFree,GAD Detail
0.011 Rectal Neoplasms NA BeFree,GAD Detail
<0.001 retinoblastoma NA BeFree Detail
<0.001 rhabdomyosarcoma NA BeFree Detail
<0.001 Seizures Further analyses will be required in order to better understand the meaning of B... BeFree 25937573 Detail
<0.001 seminoma NA BeFree Detail
0.120 Sezary syndrome NA CTD_human Detail
<0.001 Dermatologic disorders Cutaneous malignant melanoma is the leading cause of death from skin diseases an... BeFree 25174976 Detail
<0.001 Dermatologic disorders Switching from the current standard of care vemurafenib therapy to the double BR... BeFree 25185693 Detail
<0.001 Skin lesion To study the timing, prevalence and response to treatment of skin lesions in pat... BeFree 24661317 Detail
0.025 Skin Neoplasms NA BeFree,GAD Detail
0.005 Stomach Neoplasms NA LHGDN Detail
<0.001 struma ovarii NA BeFree Detail
0.002 Testicular Neoplasms NA GAD Detail
0.003 Thyroid Diseases NA BeFree,GAD Detail
0.002 Tobacco use disorder NA GAD Detail
0.002 Tongue Neoplasms NA GAD Detail
<0.001 xeroderma pigmentosum NA BeFree Detail
<0.001 diffuse large B-cell lymphoma NA BeFree Detail
0.120 Lymphoma, T-Cell, Cutaneous NA CTD_human Detail
<0.001 granular cell tumor NA BeFree Detail
<0.001 Synovial Cyst Mutated/BRAF VE1 IHC E-GBMs and anaplastic pleomorphic xanthoastrocytomas tended... BeFree 25581727 Detail
0.001 benign neoplasm NA BeFree Detail
<0.001 Hutchinson's Melanotic Freckle NA BeFree Detail
<0.001 Small cell carcinoma of lung NA BeFree Detail
<0.001 Adenocarcinoma of rectum The rare BRAF VK600-601E mutation as a possible indicator of poor prognosis in r... BeFree 25636897 Detail
<0.001 Malignant neoplasm of mouth NA BeFree Detail
<0.001 Malignant neoplasm of anus In conclusion, both KRAS and BRAF mutations are rare in anal cancer. BeFree 25244542 Detail
<0.001 uterine cancer NA BeFree Detail
<0.001 Malignant neoplasm of brain NA BeFree Detail
0.002 malignant neoplasm of frontal lobe NA GAD Detail
<0.001 Secondary malignant neoplasm of skin NA BeFree Detail
<0.001 Neurofibromatoses NA BeFree Detail
0.002 Hyperpigmentation NA GAD Detail
0.241 LEOPARD Syndrome To date, PTPN11, RAF1, and BRAF have been reported to be causal for NSML. BeFree,CLINVAR,ORPHANET 25423878 Detail
0.001 Germ cell tumor Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in... BeFree 24812411 Detail
0.003 angiomyolipoma NA LHGDN Detail
0.001 Sarcoma, Clear Cell NA BeFree Detail
<0.001 embryonal carcinoma NA BeFree Detail
<0.001 Adenoma, Villous NA BeFree Detail
<0.001 Adenomatous Polyps NA BeFree Detail
0.124 Follicular thyroid carcinoma Although BRAF mutations are detected exclusively in papillary carcinoma, they ar... BeFree,CLINVAR 25120313 Detail
0.124 Follicular thyroid carcinoma Moreover, the outcome was not different among tumors with isolated TERT mutation... BeFree,CLINVAR 25448848 Detail
0.007 Papillary and follicular adenocarcinoma NA GAD Detail
0.121 adrenocortical carcinoma NA BeFree,CTD_human Detail
0.001 Carcinoma, Endometrioid NA BeFree Detail
0.005 Medullary carcinoma NA BeFree,GAD Detail
<0.001 mucoepidermoid carcinoma NA BeFree Detail
<0.001 Carcinoma, Signet Ring Cell NA BeFree Detail
0.001 cholangiocarcinoma NA BeFree Detail
0.002 Cystadenocarcinoma, Mucinous NA GAD Detail
0.007 Cystadenocarcinoma, Serous NA GAD Detail
0.003 Cystadenoma, Serous NA BeFree,LHGDN Detail
0.003 gliosarcoma NA LHGDN Detail
0.002 Nerve Sheath Tumors NA GAD Detail
<0.001 Melanoma, Amelanotic A novel BRAF mutation in association with primary amelanotic melanoma with oral ... BeFree 24393566 Detail
<0.001 Nevus, Blue NA BeFree Detail
0.003 Epithelioid and spindle cell nevus NA BeFree,LHGDN Detail
0.121 Neuroendocrine Tumors NA BeFree,CTD_human Detail
0.001 Nevi and Melanomas We hypothesized that BRAF-induced senescence, as demonstrated in nevi and melano... BeFree 24471909 Detail
0.004 uveal melanoma NA BeFree Detail
<0.001 Shprintzen syndrome NA BeFree Detail
<0.001 Dermatitis acneiform NA BeFree Detail
<0.001 pancreatic carcinoma NA BeFree Detail
<0.001 Squamous cell carcinoma of penis NA BeFree Detail
0.002 Medullary carcinoma of thyroid NA BeFree Detail
<0.001 Carcinoma, Lewis Lung NA BeFree Detail
<0.001 Compound nevus of skin NA BeFree Detail
<0.001 Multiple tumors NA BeFree Detail
<0.001 Lobular panniculitis NA BeFree Detail
0.004 Turcot syndrome (disorder) NA BeFree Detail
<0.001 Perianal fistula NA BeFree Detail
<0.001 Isovaleryl-CoA dehydrogenase deficiency NA BeFree Detail
<0.001 Stage III Colon Cancer NA BeFree Detail
<0.001 Malignant neoplasm of colon stage IV NA BeFree Detail
<0.001 Malignant Childhood Neoplasm Mutated BRAF proteins are being identified in an increasing number of pediatric ... BeFree 24857135 Detail
<0.001 Metastatic papillary thyroid carcinoma NA BeFree Detail
<0.001 stage III melanoma BRAF mutation is an indicator of poor prognosis in patients with stage III melan... BeFree 24602025 Detail
<0.001 stage III melanoma However, the chief limitation of continuous BRAF inhibition is that the majority... BeFree 25746037 Detail
<0.001 Squamous cell carcinoma of esophagus NA BeFree Detail
<0.001 anal carcinoma KRAS and BRAF mutations in anal carcinoma. BeFree 25244542 Detail
<0.001 gallbladder adenocarcinoma NA BeFree Detail
<0.001 Acinar cell carcinoma of pancreas Comprehensive genomic profiling of a large series of PACCs (n=44) identified rec... BeFree 25266736 Detail
<0.001 cervical adenocarcinoma NA BeFree Detail
<0.001 refractory hairy cell leukemia Treatment of refractory hairy cell leukemia with a BRAF-inhibitor: lessons to be... BeFree 24789721 Detail
<0.001 refractory hairy cell leukemia Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. BeFree 26352686 Detail
0.004 Solid tumour BRAF mutation testing in solid tumors: a methodological comparison. BeFree 25132480 Detail
0.004 Solid tumour BRAF mutations can be found in various solid tumors. BeFree 25784606 Detail
<0.001 Ovarian Teratoma NA BeFree Detail
<0.001 high-grade childhood cerebral astrocytoma NA BeFree Detail
<0.001 Oligodendroglioma, Childhood Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediat... BeFree 25794445 Detail
<0.001 juvenile pilocytic astrocytoma NA BeFree Detail
0.001 diffuse astrocytoma Pediatric LGG show alterations in FGFR1 and BRAF in pilocytic astrocytomas and F... BeFree 25664944 Detail
<0.001 cervix carcinoma NA BeFree Detail
0.001 Multiple polyps NA BeFree Detail
<0.001 inflammatory myofibroblastic tumor NA BeFree Detail
<0.001 Tubular adenoma KRAS and BRAF mutations were mutually exclusive in TAs and SPs. BeFree 25734426 Detail
<0.001 Tubulovillous adenoma Traditional serrated adenoma with serrated dysplasia had a significantly higher ... BeFree 24603588 Detail
<0.001 Nodular melanoma BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular ... BeFree 24710085 Detail
<0.001 Nodular melanoma BRAF V600 mutations were detected in 18.8% of acral lentiginous melanomas (ALMs)... BeFree 25051202 Detail
<0.001 Nodular melanoma Associations with BRAF mutation were as follows: male gender [odds ratio (OR) = ... BeFree 25357015 Detail
0.002 Superficial spreading malignant melanoma of skin BRAF V600 mutations were detected in 18.8% of acral lentiginous melanomas (ALMs)... BeFree 25051202 Detail
0.002 Superficial spreading malignant melanoma of skin BRAF and NRAS mutations were more frequent in nodular and superficial spreading ... BeFree 25357015 Detail
0.002 Superficial spreading malignant melanoma of skin BRAF mutation was associated with younger age (OR = 1.734; P < .001), trunk loca... BeFree 25819940 Detail
<0.001 Struma ovarii, malignant NA BeFree Detail
<0.001 anaplastic astrocytoma As many childhood gliomas are associated with activation of BRAF, we have explor... BeFree 25981859 Detail
0.134 pilocytic astrocytoma In case 3, deletions involving BRAF and FAM131B were observed in both a primary ... BeFree,ORPHANET 25040262 Detail
0.134 pilocytic astrocytoma The KIAA1549:BRAF fusion gene is considered a driver genetic event in pilocytic ... BeFree,ORPHANET 25382612 Detail
0.134 pilocytic astrocytoma Pediatric LGG show alterations in FGFR1 and BRAF in pilocytic astrocytomas and F... BeFree,ORPHANET 25664944 Detail
0.134 pilocytic astrocytoma These results indicate that pODGs with the KIAA1549-BRAF fusion may represent a ... BeFree,ORPHANET 25794445 Detail
0.134 pilocytic astrocytoma The molecular data on PA support a key role for the BRAF oncogene in the pathoge... BeFree,ORPHANET 25976257 Detail
0.134 pilocytic astrocytoma KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in... BeFree,ORPHANET 26083571 Detail
0.134 pilocytic astrocytoma BRAF Fusion Analysis in Pilocytic Astrocytomas: KIAA1549-BRAF 15-9 Fusions Are M... BeFree,ORPHANET 26222501 Detail
<0.001 anaplastic oligodendroglioma NA BeFree Detail
<0.001 Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse NA BeFree Detail
<0.001 Iodine deficiency syndrome BRAF mutation analysis in thyroid nodules with indeterminate cytology: our exper... BeFree 25194426 Detail
<0.001 Human papilloma virus infection NA BeFree Detail
<0.001 intrahepatic cholangiocarcinoma NA BeFree Detail
<0.001 Adenoma of lung NA BeFree Detail
<0.001 Syringocystadenoma No BRAF mutation could be detected in 3 syringocystadenoma papillifera secondari... BeFree 25532942 Detail
0.001 Acral Lentiginous Malignant Melanoma BRAF V600 mutations were more frequent in late-stage ALMs than in early-stage AL... BeFree 25051202 Detail
0.001 Malignant melanoma of conjunctiva NA BeFree Detail
<0.001 Malignant melanoma of iris NA BeFree Detail
<0.001 Malignant melanoma of choroid NA BeFree Detail
<0.001 Multiple malignancy BRAF mutations: signaling, epidemiology, and clinical experience in multiple mal... BeFree 24955706 Detail
0.001 Malignant neoplasm of pancreas NA BeFree Detail
<0.001 Carcinoma of anal margin KRAS and BRAF mutations in anal carcinoma. BeFree 25244542 Detail
<0.001 Squamous cell carcinoma of tongue BRAF and NRF2 mutations, which are novel in TSCC, were demonstrated in one sampl... BeFree 25234657 Detail
<0.001 Atypical endometrial hyperplasia NA BeFree Detail
<0.001 pilocytic astrocytoma of cerebellum NA BeFree Detail
<0.001 Hairy cell leukemia variant NA BeFree Detail
<0.001 juvenile myelomonocytic leukemia NA BeFree Detail
<0.001 Trichoepithelioma Our results indicate that activation of the RAS-mitogen-activated protein kinase... BeFree 25532942 Detail
0.001 Malignant neoplasm of prostate The genetic basis of 50% to 60% of prostate cancer (PCa) is attributable to rear... BeFree 25203299 Detail
<0.001 Hematologic Neoplasms NA BeFree Detail
0.002 Craniofacial Abnormalities NA GAD Detail
<0.001 syringocystadenoma papilliferum Our results indicate that activation of the RAS-mitogen-activated protein kinase... BeFree 25532942 Detail
<0.001 papillary craniopharyngioma NA BeFree Detail
<0.001 Desmoplastic infantile astrocytoma NA BeFree Detail
0.002 Follicular neoplasm Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation c... BeFree 24947099 Detail
<0.001 Leukemia, Prolymphocytic, B-Cell NA BeFree Detail
0.005 endometrial carcinoma NA BeFree,GAD Detail
0.002 Secondary malignant neoplasm of liver Three factors were found to be independent predictors of poor disease-free survi... BeFree 25162714 Detail
<0.001 Benign neurologic neoplasms NA BeFree Detail
0.002 Recurrent tumor NA BeFree Detail
0.001 Squamous cell carcinoma of skin However vemurafenib, a type I mutant BRAF V600 inhibitor, induces an array of pr... BeFree 25185693 Detail
0.001 Squamous cell carcinoma of skin Factors influencing the development of cutaneous squamous cell carcinoma in pati... BeFree 25748298 Detail
0.121 Costello syndrome (disorder) NA BeFree,CTD_human Detail
0.144 Carcinogenesis Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid car... BeFree,CTD_human 24770869 Detail
0.144 Carcinogenesis Our results indicate that activation of the RAS-mitogen-activated protein kinase... BeFree,CTD_human 25532942 Detail
0.144 Carcinogenesis Deregulation of the CXCR4/CXCL12 axis was reported in melanoma tumorigenesis whi... BeFree,CTD_human 25839711 Detail
0.144 Carcinogenesis Well-known genetic bases for the carcinogenesis of CRC include chromosomal chang... BeFree,CTD_human 26469098 Detail
0.001 prostate carcinoma The genetic basis of 50% to 60% of prostate cancer (PCa) is attributable to rear... BeFree 25203299 Detail
0.009 Hashimoto Disease NA BeFree,GAD Detail
0.002 Progressive Neoplastic Disease Moreover, early adaptive responses limit the initial efficacy of BRAF inhibition... BeFree 25344914 Detail
0.002 Progressive Neoplastic Disease Despite major advancements in targeted therapy of metastatic melanoma, most pati... BeFree 25602684 Detail
0.002 Progressive Neoplastic Disease Continuation of vemurafenib after PD might be beneficial in some patients becaus... BeFree 25980594 Detail
<0.001 Stage IV Colorectal Cancer KRAS exon 2 and BRAF codon 600 were analyzed in patients with stage II and III C... BeFree 24889488 Detail
<0.001 breast carcinoma NA BeFree Detail
0.002 stomach carcinoma The results demonstrated that EGFR phosphorylation was markedly inhibited in gas... BeFree 25625229 Detail
0.002 stomach carcinoma Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastri... BeFree 25815786 Detail
0.002 stomach carcinoma BRAF activated non-coding RNA (BANCR) promoting gastric cancer cells proliferati... BeFree 26248136 Detail
<0.001 skin carcinoma NA BeFree Detail
0.002 Central neuroblastoma Using the Snapshot assay, mutation statuses were detected for EGFR, Kirsten rate... BeFree 24823994 Detail
<0.001 Multiple nevi Multiple AM in Caucasians is very rare.BRAF mutations are possible, especially i... BeFree 24942556 Detail
<0.001 Multiple nevi Cutaneous malignant tumors are the most frequent adverse events of BRAF inhibito... BeFree 25651238 Detail
<0.001 Dissecting aneurysm of the thoracic aorta NA BeFree Detail
<0.001 Malignant neoplasm of kidney NA BeFree Detail
<0.001 Poorly differentiated carcinoma NA BeFree Detail
<0.001 Central nervous system lesion NA BeFree Detail
<0.001 biliary tract cancer NA BeFree Detail
<0.001 Well Differentiated Oligodendroglioma NA BeFree Detail
<0.001 malignant peripheral nerve sheath tumor TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promot... BeFree 25035100 Detail
<0.001 perineurioma NA BeFree Detail
<0.001 Lafora disease NA BeFree Detail
<0.001 endocrine carcinoma NA BeFree Detail
<0.001 premalignant lesion NA BeFree Detail
<0.001 Colorectal cancer recurrent NA BeFree Detail
<0.001 Rhabdoid Tumor of the Kidney NA BeFree Detail
<0.001 Adenocarcinoma of lung, stage IV NA BeFree Detail
<0.001 Hyperkeratosis NA BeFree Detail
<0.001 Advanced cancer NA BeFree Detail
<0.001 Intraepithelial Neoplasia NA BeFree Detail
0.016 ovarian neoplasm NA BeFree,GAD,LHGDN Detail
0.153 Microsatellite Instability NA CTD_human,GAD Detail
<0.001 autoimmune thyroiditis NA BeFree Detail
<0.001 cancer recurrence The evaluation of XIAP expression and BRAF mutational analysis was more useful f... BeFree 24124924 Detail
<0.001 precancerous lesions DNA was isolated from paired normal and tumoral tissues in 78 tubular adenomas (... BeFree 25734426 Detail
<0.001 High weight High weight, hip, waist, WHR and BMI were associated with an increased risk of B... BeFree 24918610 Detail
<0.001 Polyp of large intestine NA BeFree Detail
0.002 Papillomavirus Infections NA GAD Detail
<0.001 Chromosome 17 trisomy NA BeFree Detail
0.012 Malignant neoplasm of ovary NA BeFree,GAD Detail
<0.001 Stage IV Esophageal Squamous Cell Carcinoma NA BeFree Detail
<0.001 Nevus cell nevus NA BeFree Detail
<0.001 Squamous cell carcinoma of the head and neck NA BeFree Detail
0.002 Chromosomal Instability NA GAD Detail
<0.001 Myxoid cyst Mutated/BRAF VE1 IHC E-GBMs and anaplastic pleomorphic xanthoastrocytomas tended... BeFree 25581727 Detail
<0.001 Dendritic Cell Sarcoma, Follicular NA BeFree Detail
<0.001 Morphologically altered structure The aim of the present study was to determine the frequency of KRAS and BRAF mut... BeFree 25050586 Detail
0.001 Lymphocytic infiltration NA BeFree Detail
<0.001 Neoplasm of temporal lobe NA BeFree Detail
0.004 Traditional Serrated Adenoma Traditional serrated adenoma with serrated dysplasia had a significantly higher ... BeFree 24603588 Detail
0.004 Traditional Serrated Adenoma We found that two SSAs and one TSA had BRAF mutation, while one TSA had KRAS mut... BeFree 24961182 Detail
0.004 Traditional Serrated Adenoma Thus, the BRAF mutant traditional serrated adenoma represents an important precu... BeFree 25216220 Detail
0.004 Traditional Serrated Adenoma The two LST lesions with BRAF mutation were pathologically proven to be serrated... BeFree 25551625 Detail
<0.001 Poorly Differentiated Thyroid Carcinoma NA BeFree Detail
0.002 Papillary microcarcinoma NA BeFree Detail
0.567 Cardio-facio-cutaneous syndrome New BRAF knockin mice provide a pathogenetic mechanism of developmental defects ... BeFree,CLINVAR,CTD_human,MGD,ORPHANET,UNIPROT 25035421 Detail
0.120 Hashimoto-Pritzker syndrome NA ORPHANET Detail
<0.001 Desmoplastic spindle and epithelioid cell melanocytic nevus of skin NA BeFree Detail
<0.001 Pancreatic intraepithelial neoplasia NA BeFree Detail
0.001 Adenoma of large intestine NA BeFree Detail
<0.001 Myopericytoma NA BeFree Detail
<0.001 Eruptive melanocytic nevi NA BeFree Detail
<0.001 papillary renal cell carcinoma NA BeFree Detail
<0.001 Astrocytoma, low grade NA BeFree Detail
<0.001 Non-toxic nodular goiter NA BeFree Detail
0.001 Congenital melanocytic nevus BRAF mutations are also associated with neurocutaneous melanocytosis and large/g... BeFree 25490715 Detail
0.002 Adenocarcinoma of large intestine NA BeFree Detail
<0.001 Torre-Muir syndrome NA BeFree Detail
<0.001 Colorectal Traditional Serrated Adenoma NA BeFree Detail
<0.001 Colorectal Villous Adenoma NA BeFree Detail
<0.001 Desmoplastic melanoma NA BeFree Detail
<0.001 Hereditary Malignant Neoplasm NA BeFree Detail
<0.001 High Grade Intraepithelial Neoplasia NA BeFree Detail
<0.001 Invasive Carcinoma NA BeFree Detail
<0.001 Leptomeningeal Melanoma Prolonged survival of a patient with metastatic leptomeningeal melanoma treated ... BeFree 25962795 Detail
<0.001 Metastatic Malignant Peripheral Nerve Sheath Tumor NA BeFree Detail
<0.001 Mucinous Neoplasm NA BeFree Detail
0.002 Necrotic changes (finding) NA GAD Detail
<0.001 optic nerve astrocytoma NA BeFree Detail
<0.001 Ovarian Serous Adenocarcinoma NA BeFree Detail
<0.001 pancreatic ductal adenocarcinoma NA BeFree Detail
<0.001 Primary Carcinoma NA BeFree Detail
<0.001 Spindle Cell Neoplasm NA BeFree Detail
<0.001 thyroid lymphoma NA BeFree Detail
<0.001 Epithelioma NA BeFree Detail
<0.001 mature teratoma The molecular profile of the adenocarcinoma showed a mutation in KRAS and wild-t... BeFree 25039399 Detail
<0.001 anal squamous cell carcinoma NA BeFree Detail
<0.001 Mammary Neoplasms NA BeFree Detail
<0.001 Desmoplastic NA BeFree Detail
<0.001 Hereditary Melanoma NA BeFree Detail
0.001 Xenograft Model PD-L1 expression defined a subset of the BRAF-mutated A375 cell line characteriz... BeFree 25223485 Detail
0.001 Rectal Tumors NA BeFree Detail
<0.001 Adenocarcinoma, Endometrioid NA BeFree Detail
<0.001 Glioblastoma multiforme NA BeFree Detail
<0.001 Colorectal Signet Ring Cell Carcinoma NA BeFree Detail
<0.001 Non-Neoplastic Disorder NA BeFree Detail
<0.001 Radiation Recall Dermatitis We describe the occurrence of RRR in three melanoma patients who had undergone r... BeFree 24743051 Detail
<0.001 SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 2 (disorder) NA BeFree Detail
<0.001 Nephrotic syndrome, type 3 NA BeFree Detail
0.001 Limb-girdle muscular dystrophy type 2A NA BeFree Detail
0.001 uterine corpus cancer NA BeFree Detail
0.006 Precursor Cell Lymphoblastic Leukemia Lymphoma NA BeFree,LHGDN Detail
<0.001 low grade glioma Chromosome band 7q34 deletions resulting in KIAA1549-BRAF and FAM131B-BRAF fusio... BeFree 25040262 Detail
<0.001 low grade glioma Pediatric LGG show alterations in FGFR1 and BRAF in pilocytic astrocytomas and F... BeFree 25664944 Detail
0.001 liver carcinoma NA BeFree Detail
<0.001 Urachal adenocarcinoma NA BeFree Detail
<0.001 Stage III Skin Melanoma Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of... BeFree 24602025 Detail
<0.001 Intramucosal Adenocarcinoma NA BeFree Detail
<0.001 Stage IV Colorectal Cancer AJCC v7 KRAS exon 2 and BRAF codon 600 were analyzed in patients with stage II and III C... BeFree 24889488 Detail
<0.001 Stage III Colon Cancer AJCC v7 NA BeFree Detail
<0.001 Colorectal Serrated Adenocarcinoma NA BeFree Detail
<0.001 TUMOR PREDISPOSITION SYNDROME NA BeFree Detail
<0.001 Micropapillary carcinoma NA BeFree Detail
<0.001 Serrated adenocarcinoma NA BeFree Detail
<0.001 Familial Nonmedullary Thyroid Cancer NA BeFree Detail
0.002 Progressive cGVHD Moreover, early adaptive responses limit the initial efficacy of BRAF inhibition... BeFree 25344914 Detail
0.002 Progressive cGVHD Despite major advancements in targeted therapy of metastatic melanoma, most pati... BeFree 25602684 Detail
0.002 Progressive cGVHD Continuation of vemurafenib after PD might be beneficial in some patients becaus... BeFree 25980594 Detail
<0.001 Ovarian low malignant potential tumour NA BeFree Detail
0.003 Melanocytic nevus of skin NA BeFree Detail
<0.001 Experimental Organism Basal Cell Carcinoma We searched for promoter methylation of hMLH1, RASSF1A, DAPK, APC, DCR1 and DCR2... BeFree 24573469 Detail
0.001 Low grade serous carcinoma KRAS and BRAF mutations are common in LGSC, leading to clinical trials targeting... BeFree 25523272 Detail
<0.001 Congenital Abnormality New BRAF knockin mice provide a pathogenetic mechanism of developmental defects ... BeFree 25035421 Detail
<0.001 acromegaly Tumorigenesis of papillary thyroid cancer is not BRAF-dependent in patients with... BeFree 25329702 Detail
0.017 papillary adenocarcinoma NA GAD Detail
0.030 adenoma In colorectal carcinogenesis, accumulation of high levels of methylation in comb... BeFree,GAD,LHGDN 24962701 Detail
0.030 adenoma We conclude that hypermethylation of MLH1, when occurs in an adenoma cell with B... BeFree,GAD,LHGDN 24964857 Detail
0.030 adenoma BRAF mutations were found in 9 (8.7%) precursor lesions, mainly associated with ... BeFree,GAD,LHGDN 25050586 Detail
0.030 adenoma Mixed effects models revealed that mutations in APC, BRAF and KRAS occur at the ... BeFree,GAD,LHGDN 25432628 Detail
0.030 adenoma Cancer (214 BRAF mutant, 122 BRAF wild type) and polyp (59 serrated polyps, 40 c... BeFree,GAD,LHGDN 25613750 Detail
0.002 Tumors of Adrenal Cortex NA GAD Detail
0.002 Alcoholic Intoxication, Chronic NA GAD Detail
0.121 ameloblastoma Activating FGFR2-RAS-BRAF mutations in ameloblastoma. BeFree,CTD_human 24993163 Detail
0.121 ameloblastoma Recently, BRAF and SMO mutations have been reported in ameloblastomas. BeFree,CTD_human 25854168 Detail
0.002 Anaplasia This review will cover several cellular signaling pathways and mechanisms, inclu... BeFree 25260367 Detail
0.002 Anaplasia Some of the main genetic changes of differentiated thyroid carcinomas, such as m... BeFree 25862857 Detail
<0.001 anthrax disease NA BeFree Detail
<0.001 Arthralgia NA BeFree Detail
<0.001 rheumatoid arthritis NA BeFree Detail
0.002 Articulation Disorders NA GAD Detail
0.132 Astrocytoma Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF... BeFree,CTD_human,GAD,LHGDN 25981859 Detail
0.003 Bladder Neoplasm NA BeFree,GAD Detail
<0.001 Malignant neoplasm of breast NA BeFree Detail
0.431 melanoma At clinically informative sites, we identified seven low-frequency point mutatio... BeFree 23382536 Detail
<0.001 Carcinoid Tumor NA BeFree Detail
0.001 Malignant neoplasm of endometrium NA BeFree Detail
0.001 Adenocarcinoma of prostate However, according to our finding, as in previous studies, the role of BRAF and ... BeFree 26299074 Detail
0.008 Rectal Carcinoma Using a database of 735 colon and rectal cancers in the Nurse's Health Study and... BeFree,GAD 25023548 Detail
0.008 Rectal Carcinoma The rare BRAF VK600-601E mutation as a possible indicator of poor prognosis in r... BeFree,GAD 25636897 Detail
0.008 Rectal Carcinoma Compared with BRAF wild type, BRAF(V600E) was a risk for poor survival (overall ... BeFree,GAD 25973534 Detail
<0.001 Malignant neoplasm of skin A better understanding of any potential association between HCL and skin cancer ... BeFree 26115047 Detail
0.002 mucinous adenocarcinoma NA BeFree Detail
Annotation

Annotations

DescrptionSourceLinks
This study of 9,643 patients characterized clinical implications of non-V600 BRAF mutations in meta... CIViC Evidence Detail
This phase II clinical trial of regorafenib (NCT01068769) examined the long term safety and efficacy... CIViC Evidence Detail
This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and e... CIViC Evidence Detail
In a phase II basket trial (NCI-MATCH), patients with solid tumors or hematologic malignancies harbo... CIViC Evidence Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycl... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
The molecular profile of the adenocarcinoma showed a mutation in KRAS and wild-type BRAF, which migh... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Further analyses will be required in order to better understand the meaning of BRAF mutations in epi... DisGeNET Detail
The aim of this study was to verify the presence of BRAF mutations in a series of six patients affec... DisGeNET Detail
NA DisGeNET Detail
We report a patient with BRAF mutant metastatic melanoma treated with the BRAFi/MEKi combination the... DisGeNET Detail
Combining a BRAF inhibitor with a MEK inhibitor, which may block paradoxical MAPK activation in BRAF... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
None of the 198 thyroid nodules were positive for K-RAS 61, N-RAS 12/13, or H-RAS 12/13 mutations.N-... DisGeNET Detail
NA DisGeNET Detail
However vemurafenib, a type I mutant BRAF V600 inhibitor, induces an array of proliferative skin dis... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
The results demonstrated that EGFR phosphorylation was markedly inhibited in gastric cancer cell lin... DisGeNET Detail
Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer. DisGeNET Detail
BRAF activated non-coding RNA (BANCR) promoting gastric cancer cells proliferation via regulation of... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Using the Snapshot assay, mutation statuses were detected for EGFR, Kirsten rate sarcoma viral oncog... DisGeNET Detail
The molecular biology of these GIST, originally defined as KIT/PDGFRA wild-type (WT), is complex due... DisGeNET Detail
Moving beyond BRAFV600 targeting, a number of other molecular subsets--such as mutations in MEK, NRA... DisGeNET Detail
The medical records of the 137 patients with >5 mm FVPTCs and known BRAF mutation status in the inte... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
BRAF and KRAS mutant traditional serrated adenomas are morphologically related but biologically disp... DisGeNET Detail
These polyps contain BRAF mutations and are prone to epigenetic methylation that ultimately silences... DisGeNET Detail
Cancer (214 BRAF mutant, 122 BRAF wild type) and polyp (59 serrated polyps, 40 conventional adenomas... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Further analyses will be required in order to better understand the meaning of BRAF mutations in epi... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Cutaneous malignant melanoma is the leading cause of death from skin diseases and is often associate... DisGeNET Detail
Switching from the current standard of care vemurafenib therapy to the double BRAF/MEK inhibition in... DisGeNET Detail
To study the timing, prevalence and response to treatment of skin lesions in patients receiving V-ra... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Mutated/BRAF VE1 IHC E-GBMs and anaplastic pleomorphic xanthoastrocytomas tended to manifest strong,... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
The rare BRAF VK600-601E mutation as a possible indicator of poor prognosis in rectal carcinoma – a ... DisGeNET Detail
NA DisGeNET Detail
In conclusion, both KRAS and BRAF mutations are rare in anal cancer. DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
To date, PTPN11, RAF1, and BRAF have been reported to be causal for NSML. DisGeNET Detail
Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Although BRAF mutations are detected exclusively in papillary carcinoma, they are also found in medu... DisGeNET Detail
Moreover, the outcome was not different among tumors with isolated TERT mutation and those with coex... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
A novel BRAF mutation in association with primary amelanotic melanoma with oral metastases. DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
We hypothesized that BRAF-induced senescence, as demonstrated in nevi and melanoma, is involved in t... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Mutated BRAF proteins are being identified in an increasing number of pediatric cancers and the deve... DisGeNET Detail
NA DisGeNET Detail
BRAF mutation is an indicator of poor prognosis in patients with stage III melanoma with a positive ... DisGeNET Detail
However, the chief limitation of continuous BRAF inhibition is that the majority of patients develop... DisGeNET Detail
NA DisGeNET Detail
KRAS and BRAF mutations in anal carcinoma. DisGeNET Detail
NA DisGeNET Detail
Comprehensive genomic profiling of a large series of PACCs (n=44) identified recurrent rearrangement... DisGeNET Detail
NA DisGeNET Detail
Treatment of refractory hairy cell leukemia with a BRAF-inhibitor: lessons to be learnt. DisGeNET Detail
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. DisGeNET Detail
BRAF mutation testing in solid tumors: a methodological comparison. DisGeNET Detail
BRAF mutations can be found in various solid tumors. DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliom... DisGeNET Detail
NA DisGeNET Detail
Pediatric LGG show alterations in FGFR1 and BRAF in pilocytic astrocytomas and FGFR1 alterations in ... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
KRAS and BRAF mutations were mutually exclusive in TAs and SPs. DisGeNET Detail
Traditional serrated adenoma with serrated dysplasia had a significantly higher frequency of BRAF mu... DisGeNET Detail
BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma. DisGeNET Detail
BRAF V600 mutations were detected in 18.8% of acral lentiginous melanomas (ALMs), 64.7% of superfici... DisGeNET Detail
Associations with BRAF mutation were as follows: male gender [odds ratio (OR) = 2.4], younger age (O... DisGeNET Detail
BRAF V600 mutations were detected in 18.8% of acral lentiginous melanomas (ALMs), 64.7% of superfici... DisGeNET Detail
BRAF and NRAS mutations were more frequent in nodular and superficial spreading melanomas (P < 0.001... DisGeNET Detail
BRAF mutation was associated with younger age (OR = 1.734; P < .001), trunk location (OR = 2.272; P ... DisGeNET Detail
NA DisGeNET Detail
As many childhood gliomas are associated with activation of BRAF, we have explored the combination o... DisGeNET Detail
In case 3, deletions involving BRAF and FAM131B were observed in both a primary and a recurrent PA. ... DisGeNET Detail
The KIAA1549:BRAF fusion gene is considered a driver genetic event in pilocytic astrocytoma. DisGeNET Detail
Pediatric LGG show alterations in FGFR1 and BRAF in pilocytic astrocytomas and FGFR1 alterations in ... DisGeNET Detail
These results indicate that pODGs with the KIAA1549-BRAF fusion may represent a subset of this rare ... DisGeNET Detail
The molecular data on PA support a key role for the BRAF oncogene in the pathogenesis of these tumor... DisGeNET Detail
KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocyto... DisGeNET Detail
BRAF Fusion Analysis in Pilocytic Astrocytomas: KIAA1549-BRAF 15-9 Fusions Are More Frequent in the ... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
BRAF mutation analysis in thyroid nodules with indeterminate cytology: our experience on surgical ma... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
No BRAF mutation could be detected in 3 syringocystadenoma papillifera secondarily arisen from a seb... DisGeNET Detail
BRAF V600 mutations were more frequent in late-stage ALMs than in early-stage ALMs. DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies. DisGeNET Detail
NA DisGeNET Detail
KRAS and BRAF mutations in anal carcinoma. DisGeNET Detail
BRAF and NRF2 mutations, which are novel in TSCC, were demonstrated in one sample each. DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Our results indicate that activation of the RAS-mitogen-activated protein kinase pathway by BRAF and... DisGeNET Detail
The genetic basis of 50% to 60% of prostate cancer (PCa) is attributable to rearrangements in E26 tr... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Our results indicate that activation of the RAS-mitogen-activated protein kinase pathway by BRAF and... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation. DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Three factors were found to be independent predictors of poor disease-free survival (DFS) by multiva... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
However vemurafenib, a type I mutant BRAF V600 inhibitor, induces an array of proliferative skin dis... DisGeNET Detail
Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibit... DisGeNET Detail
NA DisGeNET Detail
Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. DisGeNET Detail
Our results indicate that activation of the RAS-mitogen-activated protein kinase pathway by BRAF and... DisGeNET Detail
Deregulation of the CXCR4/CXCL12 axis was reported in melanoma tumorigenesis while also linked to BR... DisGeNET Detail
Well-known genetic bases for the carcinogenesis of CRC include chromosomal changes characteristic of... DisGeNET Detail
The genetic basis of 50% to 60% of prostate cancer (PCa) is attributable to rearrangements in E26 tr... DisGeNET Detail
NA DisGeNET Detail
Moreover, early adaptive responses limit the initial efficacy of BRAF inhibition, leading mostly to ... DisGeNET Detail
Despite major advancements in targeted therapy of metastatic melanoma, most patients relapse and sho... DisGeNET Detail
Continuation of vemurafenib after PD might be beneficial in some patients because remaining disease ... DisGeNET Detail
KRAS exon 2 and BRAF codon 600 were analyzed in patients with stage II and III CRC who underwent cur... DisGeNET Detail
NA DisGeNET Detail
The results demonstrated that EGFR phosphorylation was markedly inhibited in gastric cancer cell lin... DisGeNET Detail
Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer. DisGeNET Detail
BRAF activated non-coding RNA (BANCR) promoting gastric cancer cells proliferation via regulation of... DisGeNET Detail
NA DisGeNET Detail
Using the Snapshot assay, mutation statuses were detected for EGFR, Kirsten rate sarcoma viral oncog... DisGeNET Detail
Multiple AM in Caucasians is very rare.BRAF mutations are possible, especially in a high-risk set of... DisGeNET Detail
Cutaneous malignant tumors are the most frequent adverse events of BRAF inhibitors; therefore, stric... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are abs... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
The evaluation of XIAP expression and BRAF mutational analysis was more useful for the prediction of... DisGeNET Detail
DNA was isolated from paired normal and tumoral tissues in 78 tubular adenomas (TAs), 34 serrated po... DisGeNET Detail
High weight, hip, waist, WHR and BMI were associated with an increased risk of BRAF wild type tumour... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Mutated/BRAF VE1 IHC E-GBMs and anaplastic pleomorphic xanthoastrocytomas tended to manifest strong,... DisGeNET Detail
NA DisGeNET Detail
The aim of the present study was to determine the frequency of KRAS and BRAF mutations and microsate... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Traditional serrated adenoma with serrated dysplasia had a significantly higher frequency of BRAF mu... DisGeNET Detail
We found that two SSAs and one TSA had BRAF mutation, while one TSA had KRAS mutation. DisGeNET Detail
Thus, the BRAF mutant traditional serrated adenoma represents an important precursor of the aggressi... DisGeNET Detail
The two LST lesions with BRAF mutation were pathologically proven to be serrated adenoma. DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic ap... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
BRAF mutations are also associated with neurocutaneous melanocytosis and large/giant congenital mela... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
The molecular profile of the adenocarcinoma showed a mutation in KRAS and wild-type BRAF, which migh... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
PD-L1 expression defined a subset of the BRAF-mutated A375 cell line characterized by a highly invas... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
We describe the occurrence of RRR in three melanoma patients who had undergone radiotherapy for meta... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Chromosome band 7q34 deletions resulting in KIAA1549-BRAF and FAM131B-BRAF fusions in pediatric low-... DisGeNET Detail
Pediatric LGG show alterations in FGFR1 and BRAF in pilocytic astrocytomas and FGFR1 alterations in ... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after p... DisGeNET Detail
NA DisGeNET Detail
KRAS exon 2 and BRAF codon 600 were analyzed in patients with stage II and III CRC who underwent cur... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Moreover, early adaptive responses limit the initial efficacy of BRAF inhibition, leading mostly to ... DisGeNET Detail
Despite major advancements in targeted therapy of metastatic melanoma, most patients relapse and sho... DisGeNET Detail
Continuation of vemurafenib after PD might be beneficial in some patients because remaining disease ... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
We searched for promoter methylation of hMLH1, RASSF1A, DAPK, APC, DCR1 and DCR2 genes and BRAF muta... DisGeNET Detail
KRAS and BRAF mutations are common in LGSC, leading to clinical trials targeting the MAPK pathway. DisGeNET Detail
New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic ap... DisGeNET Detail
Tumorigenesis of papillary thyroid cancer is not BRAF-dependent in patients with acromegaly. DisGeNET Detail
NA DisGeNET Detail
In colorectal carcinogenesis, accumulation of high levels of methylation in combination with BRAF mu... DisGeNET Detail
We conclude that hypermethylation of MLH1, when occurs in an adenoma cell with BRAF oncogenic mutati... DisGeNET Detail
BRAF mutations were found in 9 (8.7%) precursor lesions, mainly associated with serrated polyps and ... DisGeNET Detail
Mixed effects models revealed that mutations in APC, BRAF and KRAS occur at the transition from norm... DisGeNET Detail
Cancer (214 BRAF mutant, 122 BRAF wild type) and polyp (59 serrated polyps, 40 conventional adenomas... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Activating FGFR2-RAS-BRAF mutations in ameloblastoma. DisGeNET Detail
Recently, BRAF and SMO mutations have been reported in ameloblastomas. DisGeNET Detail
This review will cover several cellular signaling pathways and mechanisms, including RET/PTC, RAS, B... DisGeNET Detail
Some of the main genetic changes of differentiated thyroid carcinomas, such as mutations in BRAF and... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
At clinically informative sites, we identified seven low-frequency point mutations (0.2%-4.7%), incl... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
However, according to our finding, as in previous studies, the role of BRAF and EGFR gene mutations ... DisGeNET Detail
Using a database of 735 colon and rectal cancers in the Nurse's Health Study and the Health Professi... DisGeNET Detail
The rare BRAF VK600-601E mutation as a possible indicator of poor prognosis in rectal carcinoma – a ... DisGeNET Detail
Compared with BRAF wild type, BRAF(V600E) was a risk for poor survival (overall survival; 5 years: 6... DisGeNET Detail
A better understanding of any potential association between HCL and skin cancer is highly relevant g... DisGeNET Detail
NA DisGeNET Detail

Overlapped Transcript Coordinates

Gene Transcript ID Exon Number Chromosome Start Stop Type Amino Mutation Transcript Position Links

Overlapped Transcript

Gene Transcript ID Chromosome Start Stop Links
Gene
-
dbSNP
rs386626619 dbSNP
Genome
hg19
Position
chr7:140,419,127-140,624,729
Variant Type
snv
Variant (CIViC) (CIViC Variant)
Non-V600
Variant URL (CIViC Variant)
https://civic.genome.wustl.edu/links/variants/2408
Variant (CIViC) (CIViC Variant)
EXON 15 MUTATION
Variant URL (CIViC Variant)
https://civic.genome.wustl.edu/links/variants/2650
Genome browser